GGrantIndex
Sort

15,842 grants matching pancreatic cancer

HTS enabled examination of drug combinations

$1,215,806
Craig Thomas · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR

SBIR Phase II: nCapsule Personalized Cancer Screening for Colorectal Cancer Treatment Regimens

$1,213,619
Armin T Rad · Encapsulate Llc · · FY2025 · TIP

Preclinical drug development in pancreatic cancer

$1,212,844
Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

GI RESEARCH ON ABSORPTIVE &SECRETORY PROCESSES

$1,212,493
Tufts Medical Center · P30 · FY2005 · DK

Tyrosine kinase receptors (VEGFR and EGFR) regulate normal automaticity of heart pacemaker, the sinoatrial node.

$1,212,420
Edward Lakatta · National Institute On Aging · ZIA · FY2025 · AG

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs

$1,211,401
Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Targeting diet-induced promotion of Kras-initiated pancreatic adenocarcinoma

$1,207,024
Guido Erwin Michael Eibl · University Of California Los Angeles · P01 · FY2013 · CA

Cancer Prevention-Interception Targeted Agent Discovery Program at Fox Chase Cancer Center

$1,207,007
Margie L. Clapper · Research Inst Of Fox Chase Can Ctr · U54 · FY2023 · CA

Signal Transduction Events and the Regulation of Cell Growth

$1,205,526
Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2022 · CA

Pancreatic Cancer ARTNet Center

$1,202,713
Pankaj Kumar Singh · University Of Oklahoma Hlth Sciences Ctr · U54 · FY2024 · CA

Photodynamic Priming of Cancer and Image-guidance for Optimal Immune Response

$1,202,445
Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2023 · CA

NADPH Oxidases as Novel Targets for Cancer Therapy

$1,201,732
James Doroshow · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

NADPH Oxidases as Novel Targets for Cancer Therapy

$1,201,276
James Doroshow · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma

$1,201,109
Randall Brand · University Of Pittsburgh At Pittsburgh · U01 · FY2024 · CA

Signal Transduction Events and the Regulation of Cell Growth

$1,199,893
Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2021 · CA

First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer

$1,198,246
Alexander B Sigalov · Signablok, Inc. · R44 · FY2020 · CA

Pathways that Suppress or Accelerate Premalignant Progression of Squamous Cancer

$1,194,199
Stuart H. Yuspa · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Combinational Immunotherapies to Amplify Vaccine Induced

$1,193,000
Johns Hopkins University · U19 · FY2005 · CA

Great Lakes/New England Clinical Epidemiology/Validation

$1,191,805
University Of Michigan At Ann Arbor · U01 · FY2005 · CA

Overhauser Enhanced Magnetic Resonance Imaging (OMRI)

$1,191,129
Murali Krishna · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Time Domian Electron Paramagnetic Resonance Imaging

$1,191,129
Murali Krishna · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Texas Medical Center Digestive Diseases Center

$1,191,053
Hashem B El-Serag · Baylor College Of Medicine · P30 · FY2023 · DK

Genomic and genetic studies of endocrine cancers

$1,189,352
Electron Kebebew · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Academic-Industrial Partnership to Develop Clinical Tools for Algorithmic Irreversible Electroporation of Inoperable Tumors

$1,189,042
Michael Benjamin Sano · North Carolina State University Raleigh · R01 · FY2025 · CA

Texas Medical Center Digestive Diseases Center

$1,188,057
Hashem B El-Serag · Baylor College Of Medicine · P30 · FY2024 · DK